Low-density lipoprotein (ldl) apheresis

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Low-density lipoprotein (LDL) apheresis, also referred to as lipoprotein apheresis or lipid apheresis, is a procedure that involves extracorporeal treatment of plasma to remove apoprotein (apo) B-containing lipoproteins followed by reinfusion of the processed blood. This specialized adjunctive procedure is reserved for patients who have severe refractory hypercholesterolemia after treatment with maximally tolerated LDL-lowering medications in combination with lifestyle changes, most often in the context of the genetic disorder familial hypercholesterolemia (FH). It is estimated that 2–4 % of patients with FH meet the criteria for initiating LDL apheresis, which means that about 1 in 12,500 to 1 in 50,000 individuals may be candidates for LDL apheresis. The approximately 3-h procedure acutely lowers the plasma LDL cholesterol concentration by up to 85 %, as well as lowering the concentrations of Lp(a) and remnant lipoproteins. The procedure has several documented cardiovascular benefits, including a 72 % reduction in cardiovascular events compared to standard medical therapy in a long-term open label trial.

Original languageEnglish (US)
Title of host publicationDyslipidemias: Pathophysiology, Evaluation and Management
PublisherHumana Press Inc.
Pages483-497
Number of pages15
ISBN (Print)9781607614241, 9781607614234
DOIs
StatePublished - Jan 1 2015

Fingerprint

Blood Component Removal
LDL Lipoproteins
Lipoproteins
Hyperlipoproteinemia Type II
Inborn Genetic Diseases
Apolipoproteins B
Hypercholesterolemia
LDL Cholesterol
Life Style
Therapeutics
Lipids

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Duell, P. (2015). Low-density lipoprotein (ldl) apheresis. In Dyslipidemias: Pathophysiology, Evaluation and Management (pp. 483-497). Humana Press Inc.. https://doi.org/10.1007/978-1-60761-424-1_29

Low-density lipoprotein (ldl) apheresis. / Duell, Paul.

Dyslipidemias: Pathophysiology, Evaluation and Management. Humana Press Inc., 2015. p. 483-497.

Research output: Chapter in Book/Report/Conference proceedingChapter

Duell, P 2015, Low-density lipoprotein (ldl) apheresis. in Dyslipidemias: Pathophysiology, Evaluation and Management. Humana Press Inc., pp. 483-497. https://doi.org/10.1007/978-1-60761-424-1_29
Duell P. Low-density lipoprotein (ldl) apheresis. In Dyslipidemias: Pathophysiology, Evaluation and Management. Humana Press Inc. 2015. p. 483-497 https://doi.org/10.1007/978-1-60761-424-1_29
Duell, Paul. / Low-density lipoprotein (ldl) apheresis. Dyslipidemias: Pathophysiology, Evaluation and Management. Humana Press Inc., 2015. pp. 483-497
@inbook{e169a27e5ea44cd8aaf6cc77a2f930e5,
title = "Low-density lipoprotein (ldl) apheresis",
abstract = "Low-density lipoprotein (LDL) apheresis, also referred to as lipoprotein apheresis or lipid apheresis, is a procedure that involves extracorporeal treatment of plasma to remove apoprotein (apo) B-containing lipoproteins followed by reinfusion of the processed blood. This specialized adjunctive procedure is reserved for patients who have severe refractory hypercholesterolemia after treatment with maximally tolerated LDL-lowering medications in combination with lifestyle changes, most often in the context of the genetic disorder familial hypercholesterolemia (FH). It is estimated that 2–4 {\%} of patients with FH meet the criteria for initiating LDL apheresis, which means that about 1 in 12,500 to 1 in 50,000 individuals may be candidates for LDL apheresis. The approximately 3-h procedure acutely lowers the plasma LDL cholesterol concentration by up to 85 {\%}, as well as lowering the concentrations of Lp(a) and remnant lipoproteins. The procedure has several documented cardiovascular benefits, including a 72 {\%} reduction in cardiovascular events compared to standard medical therapy in a long-term open label trial.",
author = "Paul Duell",
year = "2015",
month = "1",
day = "1",
doi = "10.1007/978-1-60761-424-1_29",
language = "English (US)",
isbn = "9781607614241",
pages = "483--497",
booktitle = "Dyslipidemias: Pathophysiology, Evaluation and Management",
publisher = "Humana Press Inc.",

}

TY - CHAP

T1 - Low-density lipoprotein (ldl) apheresis

AU - Duell, Paul

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Low-density lipoprotein (LDL) apheresis, also referred to as lipoprotein apheresis or lipid apheresis, is a procedure that involves extracorporeal treatment of plasma to remove apoprotein (apo) B-containing lipoproteins followed by reinfusion of the processed blood. This specialized adjunctive procedure is reserved for patients who have severe refractory hypercholesterolemia after treatment with maximally tolerated LDL-lowering medications in combination with lifestyle changes, most often in the context of the genetic disorder familial hypercholesterolemia (FH). It is estimated that 2–4 % of patients with FH meet the criteria for initiating LDL apheresis, which means that about 1 in 12,500 to 1 in 50,000 individuals may be candidates for LDL apheresis. The approximately 3-h procedure acutely lowers the plasma LDL cholesterol concentration by up to 85 %, as well as lowering the concentrations of Lp(a) and remnant lipoproteins. The procedure has several documented cardiovascular benefits, including a 72 % reduction in cardiovascular events compared to standard medical therapy in a long-term open label trial.

AB - Low-density lipoprotein (LDL) apheresis, also referred to as lipoprotein apheresis or lipid apheresis, is a procedure that involves extracorporeal treatment of plasma to remove apoprotein (apo) B-containing lipoproteins followed by reinfusion of the processed blood. This specialized adjunctive procedure is reserved for patients who have severe refractory hypercholesterolemia after treatment with maximally tolerated LDL-lowering medications in combination with lifestyle changes, most often in the context of the genetic disorder familial hypercholesterolemia (FH). It is estimated that 2–4 % of patients with FH meet the criteria for initiating LDL apheresis, which means that about 1 in 12,500 to 1 in 50,000 individuals may be candidates for LDL apheresis. The approximately 3-h procedure acutely lowers the plasma LDL cholesterol concentration by up to 85 %, as well as lowering the concentrations of Lp(a) and remnant lipoproteins. The procedure has several documented cardiovascular benefits, including a 72 % reduction in cardiovascular events compared to standard medical therapy in a long-term open label trial.

UR - http://www.scopus.com/inward/record.url?scp=84956754576&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84956754576&partnerID=8YFLogxK

U2 - 10.1007/978-1-60761-424-1_29

DO - 10.1007/978-1-60761-424-1_29

M3 - Chapter

AN - SCOPUS:84956754576

SN - 9781607614241

SN - 9781607614234

SP - 483

EP - 497

BT - Dyslipidemias: Pathophysiology, Evaluation and Management

PB - Humana Press Inc.

ER -